BioCardia Announces Interim Efficacy Results in Phase III Pivotal CardiAMP Cell Therapy Heart Failure TrialGlobeNewsWire • 09/05/23
BioCardia Reports Second Quarter 2023 Business Highlights and Financial ResultsGlobeNewsWire • 08/09/23
BioCardia to Host Q2 2023 Financial Results and Corporate Update Conference Call on August 9, 2023GlobeNewsWire • 08/02/23
BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is CollectedGlobeNewsWire • 07/24/23
BioCardia Completes Submission of CardiAMP Cell Therapy System in Heart Failure to Japan's Pharmaceutical Medical Device AgencyGlobeNewsWire • 07/05/23
BioCardia Announces FDA Completes Review of Proposed Adaptive Statistical Analysis Design for Ongoing CardiAMP Cell Therapy in Heart Failure Pivotal StudyGlobeNewsWire • 06/20/23
BioCardia Announces Timing of the Next Data Safety Monitoring Board Meeting for the CardiAMP Cell Therapy in Heart Failure Pivotal StudyGlobeNewsWire • 05/23/23
BioCardia Reports First Quarter 2023 Business Highlights and Financial ResultsGlobeNewsWire • 05/10/23
BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic ApplicationsGlobeNewsWire • 05/09/23
BioCardia to Host Q1 2023 Financial Results and Corporate Update Conference Call on May 10, 2023GlobeNewsWire • 05/04/23
BioCardia Presentations at Next Generation Cardiovascular Drug Development Summit Now AvailableGlobeNewsWire • 04/28/23
BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional TherapiesGlobeNewsWire • 04/04/23
BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial ResultsGlobeNewsWire • 03/29/23
BioCardia to Host 2022 Financial Results and Corporate Update Conference Call on March 29, 2023GlobeNewsWire • 03/16/23
Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual MeetingGlobeNewsWire • 03/06/23
BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for PatientsGlobeNewsWire • 02/01/23
BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart FailureBusiness Wire • 12/06/22